Related Experiment Video

Updated: May 12, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Targeting the human epidermal growth factor receptor 2 in esophageal cancer

Khaldoun Almhanna1, Kenneth L Meredith, Sarah E Hoffe

  • 1Gastrointestinal Tumor Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA. Khaldoun.Almhanna@Moffitt.org

Cancer Control : Journal of the Moffitt Cancer Center
|April 11, 2013
PubMed

Insights

Human epidermal growth factor-2 (HER2) is crucial in esophageal cancer. While targeted therapies like trastuzumab show promise, their role in HER2-overexpressing esophageal tumors requires further investigation.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Human epidermal growth factor-2 (HER2) overexpression is a known prognostic factor in breast cancer.
  • HER2 also occurs in other cancers, including esophageal cancer, but its implications are less understood.
  • Current scoring systems for HER2 overexpression differ between breast and esophageal cancers.

Purpose of the Study:

  • To review the biological and therapeutic implications of HER2 overexpression in esophageal cancer.
  • To present the validated standard scoring system for HER2 overexpression in esophageal cancer.
  • To analyze the role of trastuzumab in HER2-overexpressing esophageal cancer.

Main Methods:

  • Review of clinical trials, including the ToGA trial.
  • Analysis of data on the HER2 cascade.
  • Presentation of the validated scoring system for HER2 in esophageal cancer.

Main Results:

  • The ToGA trial showed improved outcomes for HER2-positive advanced gastric/gastroesophageal junction tumors treated with trastuzumab plus chemotherapy.
  • Only a subset of the ToGA trial participants had esophageal or GEJ tumors with confirmed HER2 overexpression.
  • Data on HER2 overexpression in esophageal cancer specifically is limited.

Conclusions:

  • The role of trastuzumab in HER2-overexpressing esophageal cancer remains uncertain despite promising results in related cancers.
  • Further research is needed to establish definitive treatment guidelines for HER2-positive esophageal cancer.
  • A validated scoring system is crucial for accurate HER2 assessment in esophageal cancer.

More Related Videos

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...